Ország: Ausztria
Nyelv: angol
Forrás: HMA (Heads of Medicines Agencies)
marbofloxacin 5 mg
Krka d.d.
QJ01MA93
Tablet
marbofloxacin
Cats, Dogs
2012-11-21
Issued: April 2013 AN: 01879/2011 : Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marfloxin 5 mg tablets for cats and dogs Quiflox 5 mg tablets for cats and dogs Quiflox vet 5 mg tablets for cats and dogs Marbiflox 5 mg tablets for cats and dogs Marfloxin 5 mg tablets for cats and dogs (Austria, Belgium, Bulgaria, Estonia, Germany, Greece, Italy, Ireland, Netherlands, Poland, Portugal, Romania, Slovenia, Spain, United Kingdom) Quiflox 5 mg tablets for cats and dogs (Czech Republic, Hungary, Latvi a, Lithuania, Slovak Republic) Quiflox vet 5 mg tablets for cats and dogs (Finland, Sweden, Norway) Marbiflox 5 mg tablets for cats and dogs(Denmark, France,) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE: Marbofloxacin…….5 mg EXCIPIENTS: For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets. Light brownish yellow, round, biconvex, marble tablets with bevelled edges and with possible dark and white spots, scored on one side. The tablets can be divided into halves. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats and dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of infections caused by strains of microorganisms susceptible to marbofloxacin. Issued: April 2013 AN: 01879/2011 : Page 2 of 6 In dogs: skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis); urinary tract infections (UTI) associated or not with prostatitis or epididymitis; Olvassa el a teljes dokumentumot